Xilio Therapeutics, Inc.
NASDAQ:XLO
1.11 (USD) • At close December 23, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Xilio Therapeutics, Inc. |
Symbool | XLO |
Munteenheid | USD |
Prijs | 1.11 |
Beurswaarde | 48,793,461 |
Dividendpercentage | 0% |
52-weken bereik | 0.5 - 1.93 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Rene Russo BCPS, Pharm.D, Pharm.D. |
Website | https://www.xiliotx.com |
An error occurred while fetching data.
Over Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)